CoChat

A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV‐Associated Cryptococcal Meningitis

Pappas, Peter G., Chetchotisakd, Ploenchan, Larsen, Robert A., Manosuthi, Weerawat, Morris, Michele I., Anekthananon, Thomansak, Sungkanuparph, Somnuek, Supparatpinyo, Khauncahi, Nolen, Tracy L., Zimmer, Louise O., Kendrick, Amy S., Johnson, Phillip, Sobel, Jack D., Filler, Scott G. · 2009 · Clinical Infectious Diseases
Cited by 141

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cryptococcosis is a life-threatening infection among patients with human immunodeficientcy virus (HIV) infection. Therapeutic options for the treatment of central nervous system cryptococcosis are limited, especially in resource-limited settings. METHODS: We conducted a randomized, open-label, phase II trial in Thailand and the United States that compared the safety and efficacy of intravenous amphotericin B deoxycholate (AmB) 0.7 mg/kg (the standard therapy) with that of AmB 0.7 mg/kg plus fluconazole 400 mg (the low-dosage combination) or AmB 0.7 mg/kg plus fluconazole 800 mg (the high-dosage combination) administered daily for 14 days, followed by fluconazole alone at the randomized dosage (400 or 800 mg per day) for 56 days. The primary safety end point was the number of severe or life-threatening treatment-related toxicities; the primary efficacy end point was a composite of survival, neurologic stability, and negative cerebrospinal fluid culture results after 14 days of therapy. RESULTS: A total of 143 patients were enrolled. There were no differences in treatment-related toxicities among the 3 arms. Toxicity was predictable and was most often related to AmB, and it included electrolyte abnormalities, anemia, nephrotoxicity, and infusion-related events. At day 14, 41%, 27%, and 54% of patients in the standard therapy, low-dosage combination, and high-dosage combination therapy arms, respectively, demonstrated successful outcomes. A trend towards better outcomes in the combination therapy arms was seen at days 42 and 70. CONCLUSIONS: AmB plus fluconazole administered at a dosage of 800 mg for 14 days, followed by fluconazole administered at a dosage of 800 mg daily for 56 days, is well-tolerated and efficacious among HIV-positive patients with central nervous system cryptococcosis. These results have significant treatment implications and should be validated in a randomized phase III trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/599112

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 141

Metadata

Authors
Pappas, P. G., Chetchotisakd, P., Larsen, R. A., Manosuthi, W., Morris, M. I., Anekthananon, T., Sungkanuparph, S., Supparatpinyo, K., Nolen, T. L., Zimmer, L. O., Kendrick, A. S., Johnson, P., Sobel, J. D., & Filler, S. G.
Venue
Clinical Infectious Diseases
Published
2009-06-15
Volume
48
Issue
12
Pages
1775-1783
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2149684675
Cited by
141
References
1
FWCI
9.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV‐Associated Cryptococcal Meningitis. https://app.cochat.ai/papers/10.1086/599112
The paper
Pappas, P. G., Chetchotisakd, P., Larsen, R. A., Manosuthi, W., Morris, M. I., Anekthananon, T., Sungkanuparph, S., Supparatpinyo, K., Nolen, T. L., Zimmer, L. O., Kendrick, A. S., Johnson, P., Sobel, J. D., & Filler, S. G. (2009). A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV‐Associated Cryptococcal Meningitis. Clinical Infectious Diseases. https://doi.org/10.1086/599112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.